OVER DEZE PODCAST 🔗

Frequentie bijwerken:
every 21 days
Gemiddelde audiolengte:
9 minutes
Gastinterviews
Engels
Verenigde Staten
213 afleveringen
sinds 2 augustus 2017
episodic

MEEST RECENTE AFLEVERING 🔗

Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.

OUDE AFLEVERINGEN ZOEKEN

Zoek naar eerdere afleveringen van Talking Points.

VORIGE AFLEVERINGEN

The FAME 3 Trial

William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.

The PRAGUE-25 Study

Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
Disclaimer: De podcast en de illustraties die op deze pagina zijn ingesloten, zijn afkomstig van TCTMD, eigendom van de eigenaar en niet gelieerd aan of goedgekeurd door Listen Notes, Inc.